Preimplantation Genetics Diagnosis Market size to exceed $124.7 Million by 2035 | Illumina, Inc., Thermo Fisher Scientific, Agilent Technologies, CooperSurgical, Natera, Inc

The Preimplantation Genetics Diagnosis Market is undergoing a period of steady advancement driven by rising adoption of assisted reproductive technologies, growing awareness of genetic disorders, and the increasing emphasis on successful embryo selection. According to current industry insights, the market is valued at USD 61.9 million in 2025 and is projected to reach USD 124.7 million by 2035, supported by a CAGR of 8.1% from 2026 to 2035. This consistent upward trajectory reflects the growing demand for early detection of hereditary diseases, continuous improvements in genetic testing methods, and greater access to fertility care worldwide.

Clinical adoption of preimplantation genetic diagnosis (PGD) continues to grow as fertility specialists and prospective parents seek technologies capable of reducing the risk of inherited conditions, increasing implantation success, and improving pregnancy outcomes. As reproductive medicine becomes more technologically advanced, the value of PGD is expanding beyond traditional use cases to include screening for chromosomal abnormalities, single-gene disorders, and structural rearrangements. PGD also plays a pivotal role in IVF success optimization, helping clinics enhance live birth rates through targeted embryo selection and reducing the need for repeated treatment cycles.

➤ Request Free Sample PDF Report @ https://www.researchnester.com/sample-request-8019

Regional Performance Highlights

Regional adoption patterns in the Preimplantation Genetics Diagnosis Market highlight significant differences in healthcare infrastructure, cultural acceptance of IVF procedures, and regulatory environments. North America is projected to maintain a leading position, holding 42.2% of global share by the end of 2035. The region benefits from advanced reproductive technologies, strong presence of genetic testing companies, and high consumer awareness regarding early genetic screening. Supportive insurance structures for IVF treatments and ongoing investment in clinical research further reinforce market strength.

Europe continues to remain a prominent market with a stable outlook throughout the forecast period. The region's strong emphasis on reproductive health standards, combined with broad acceptance of PGD in IVF clinics, supports consistent market participation. Countries such as the U.K., Spain, and Denmark remain key contributors due to their robust fertility clinic networks and regulatory clarity surrounding genetic testing applications.

The Asia Pacific region is expected to emerge as the fastest-growing market by 2035. Factors driving this growth include rising infertility rates, increasing demand for personalized medicine, expanding fertility care infrastructure, and a rapidly growing middle-class population seeking advanced reproductive technologies. Nations such as India, Japan, South Korea, and China are accelerating the region's growth through increased investments in IVF centers, government-backed healthcare initiatives, and greater integration of next-generation sequencing technologies in genetic screening workflows.

➤ Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Preimplantation Genetics Diagnosis Report Overview here: https://www.researchnester.com/reports/preimplantation-genetics-diagnosis-market/8019

Market Segmentation

The Preimplantation Genetics Diagnosis Market is characterized by diverse applications across genetic screening categories and technological platforms. By application, the chromosomal abnormalities segment is expected to dominate with 32.4% share by 2035, driven by rising cases of aneuploidy, recurrent miscarriages, and the increasing need to improve IVF success rates. This segment plays a critical role in identifying abnormalities such as trisomy, monosomy, and structural rearrangements before embryo implantation.

Among the technology segments, Next-Generation Sequencing (NGS) holds the highest projected demand and is set to capture 42.6% of market share by 2035. NGS has transformed PGD by enabling higher accuracy, greater scalability, and comprehensive genomic coverage, making it the preferred method in modern reproductive medicine. Its ability to detect even complex genetic variations and provide high-throughput analysis has positioned NGS as the cornerstone of embryo testing in fertility clinics worldwide.

The adoption of PGD across end-use categories-including fertility clinics, hospitals, and specialized genetic testing laboratories-continues to rise as patient preference shifts toward preventive genetic solutions. Increased integration of genetic counseling services further enhances adoption, supporting informed decision-making for families undergoing IVF treatments.

➤ Discover how the Preimplantation Genetics Diagnosis Market is evolving globally - access your free sample report → https://www.researchnester.com/sample-request-8019

Top Market Trends

1. Expanding Use of Next-Generation Sequencing in Reproductive Genomics

NGS is reshaping the landscape of the Preimplantation Genetics Diagnosis Market as clinics transition away from older screening methods toward comprehensive genomic analysis. The technology provides faster turnaround times, higher accuracy, and the ability to sequence multiple embryos simultaneously. Recent years have seen fertility clinics adopt NGS for enhanced embryo viability assessment, enabling more reliable detection of chromosomal and monogenic disorders. Integration of AI-powered algorithms into NGS workflows is improving data interpretation, resulting in more precise embryo selection strategies.

2. Rising Demand for Personalized and Preventive Reproductive Care

Consumers today are increasingly proactive about managing genetic risks and optimizing pregnancy outcomes, leading to higher demand for PGD services. Couples with a history of hereditary diseases-such as cystic fibrosis, thalassemia, or BRCA-linked cancers-are adopting PGD to reduce transmission risk. The expansion of personalized reproductive care programs that combine genetic counseling, advanced diagnostic tools, and customized IVF protocols is further enhancing awareness and market penetration. Additionally, global fertility tourism is fueling demand as patients seek cost-effective access to advanced screening technologies.

3. Integration of AI and Digital Platforms in Embryo Assessment

AI and machine learning are playing a vital role in modern fertility treatment, especially in embryo grading, anomaly detection, and predicting implantation success. Digital tools capable of analyzing embryo development patterns offer clinics advanced decision-support systems that complement PGD. Recent developments include cloud-based platforms enabling real-time genomic data sharing between laboratories and fertility specialists. This digital transformation is streamlining workflows and improving the accuracy of genetic evaluations.

➤ Stay ahead of the curve with the latest Preimplantation Genetics Diagnosis Market trends. Claim your sample report → https://www.researchnester.com/sample-request-8019

Recent Company Developments

The Preimplantation Genetics Diagnosis Market is shaped by contributions from leading diagnostic companies, reproductive technology providers, and genomics innovators. Below are five notable company developments from the past 12 months:

1. Illumina, Inc.

Illumina expanded its reproductive health solutions portfolio by introducing enhanced sequencing kits designed specifically for embryo genetic analysis. These improvements aim to increase accuracy and reduce sequencing costs for fertility clinics worldwide.

2. Thermo Fisher Scientific

The company announced strategic investments in reproductive genomics, including new partnerships with IVF centers to integrate advanced PGD workflows using Thermo Fisher's high-throughput sequencing platforms.

3. Agilent Technologies

Agilent launched updated microarray technology supporting comprehensive chromosomal analysis for PGD applications. The updated platform offers faster processing and improved sensitivity, benefiting both laboratories and clinicians.

4. CooperSurgical

A leader in fertility solutions, CooperSurgical expanded its genetic testing services through targeted acquisitions in the reproductive diagnostics field. The company also unveiled upgraded tools supporting embryo biopsy accuracy and consistency.

5. Natera, Inc.

Natera strengthened its footprint in reproductive genetics by enhancing its cloud-based diagnostics ecosystem. Recent updates allow fertility clinics to streamline testing procedures and access improved genetic risk assessment tools.

➤ Request Free Sample PDF Report @ https://www.researchnester.com/sample-request-8019

Related News -
https://www.linkedin.com/pulse/why-does-hydrophobic-interaction-chromatography-market-dlawf

https://www.linkedin.com/pulse/how-transportation-management-system-market-redefining-ouswf

Contact Data

AJ Daniel
Corporate Sales, USA
Research Nester
77 Water Street 8th Floor, New York, 10005
Email: info@researchnester.com
USA Phone: +1 646 586 9123
Europe Phone: +44 203 608 5919

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

This release was published on openPR.